Side effects observed during intermittent rifampicin therapy.
D000917:Antibody Formation; D000937:Antigen-Antibody Reactions; D004359:Drug Therapy, Combination; D005334:Fever / Q000139:chemically induced; D006261:Headache / Q000139:chemically induced; D006801:Humans; D007538:Isoniazid / Q000627:therapeutic use; D009325:Nausea / Q000139:chemically induced; D011696:Purpura, Thrombocytopenic / Q000139:chemically induced; D011736:Pyridoxine / Q000627:therapeutic use; D012293:Rifampin / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D013307:Streptomycin / Q000627:therapeutic use; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy
D011736:Pyridoxine; D007538:Isoniazid; D012293:Rifampin; D013307:Streptomycin